SCHEDULE: JPMorgan Chase Discloses Insmed Stake

JPMorgan Chase & Co. has filed a Schedule 13G, reporting beneficial ownership of 4.7% of Insmed Incorporated's common stock as of June 30, 2026.

Summary

• JPMorgan Chase & Co. has reported beneficial ownership of 10,365,622 shares of Insmed Incorporated common stock.
• This represents 4.7% of the total class of securities.
• The filing is an amendment (Amendment No. 2) to a Schedule 13G.
• The event date requiring this filing was June 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership by a large financial institution and does not contain operational or strategic updates.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically made by institutional investors who acquire more than 5% of a company's stock, indicating a significant passive investment. JPMorgan Chase & Co. is a major global financial institution, and its filings often reflect substantial holdings across various public companies.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding a significant institutional investor's stake in Insmed Incorporated, which can influence market perception.

Key Dates

Keywords

Insmed Incorporated, JPMorgan Chase & Co., Schedule 13G, Beneficial Ownership, Common Stock, Securities Exchange Act